ArticleNature communications2014
Resolving cancer-stroma interfacial signalling and interventions with micropatterned tumour-stromal assays.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.Oncotarget · 2016Pooled it
- Immune niche composed of C1QNature communications · 2026Article
- Article
- Bone Metastasis in Estrogen Receptor-Positive Breast Cancer: Molecular Insights and Therapeutic Advances.International journal of molecular sciences · 2026Review
- Microfabricated Organ-Specific Models of Tumor Microenvironments.Annual review of biomedical engineering · 2025Review
- Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution.Cancer discovery · 2025Article
- Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients.Nature communications · 2024Article
- Reversine inhibits proliferation and induces apoptosis of human osteosarcoma cells through targeting MEK1.Journal of bone oncology · 2024Article
- Cancer 3D Models for Metallodrug Preclinical Testing.International journal of molecular sciences · 2023Review
- Independent control over cell patterning and adhesion on hydrogel substrates for tissue interface mechanobiology.iScience · 2023Article
- The Applications and Challenges of the Development ofCellular and molecular bioengineering · 2023Review
- Article
- Engineered in vitro tumor models for cell-based immunotherapy.Acta biomaterialia · 2021Review
- Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.Annals of biomedical engineering · 2021Review
- PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.NPJ precision oncology · 2021Article
- Article
- Applicability of drug response metrics for cancer studies using biomaterials.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Article
- Biomechanical Microenvironment Regulates Fusogenicity of Breast Cancer Cells.ACS biomaterials science & engineering · 2019Article
- Spatial Regulation of Mitochondrial Heterogeneity by Stromal Confinement in Micropatterned Tumor Models.Scientific reports · 2019Article
- Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.The Journal of experimental medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
Abstract
Tumour-stromal interactions are a determining factor in cancer progression. In vivo, the interaction interface is associated with spatially resolved distributions of cancer and stromal phenotypes. Here, we establish a micropatterned tumour-stromal assay (μTSA) with laser capture microdissection to control the location of co-cultured cells and analyse bulk and interfacial tumour-stromal signalling in driving cancer progression. μTSA reveals a spatial distribution of phenotypes in concordance with human oestrogen receptor-positive (ER+) breast cancer samples, and heterogeneous drug activity relative to the tumour-stroma interface. Specifically, an unknown mechanism of reversine is shown in targeting tumour-stromal interfacial interactions using ER+ MCF-7 breast cancer and bone marrow-derived stromal cells. Reversine suppresses MCF-7 tumour growth and bone metastasis in vivo by reducing tumour stromalization including collagen deposition and recruitment of activated stromal cells. This study advocates μTSA as a platform for studying tumour microenvironmental interactions and cancer field effects with applications in drug discovery and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.